



COMMUNIVET™

Overview/description

It's been a year! What have we learned about velagliflozin?

In this live webcast, **Dr. Susan Little** will focus on the recent advancements in treating diabetes mellitus in cats. While we can't say goodbye to insulin yet, new oral medications have revolutionized care for diabetic cats. Dr. Little will review a range of treatment options, and she will discuss the best candidate patients for each one in the context of providing a Spectrum of Care. She will also share her experience with velagliflozin (Senvelgo®) by reviewing cases involving diabetic patients from her hospital.

Speaker's bio and credentials



Susan Little, DVM, Dipl. ABVP (Feline Practice)

Dr. Susan Little received her Bachelor of Science degree from Dalhousie University (Nova Scotia, Canada) and her DVM from the Ontario Veterinary College, University of Guelph. She has been board certified in Feline Practice since 1997. She is part owner of two feline specialty practices in Ottawa, Canada. She has served on the board of the International Council for Veterinary Assessments, the American Association of Feline Practitioners (now the Feline Veterinary Medical Association), and the Winn Feline Foundation (now the EveryCat Foundation). She is a peer reviewer for veterinary journals as well as the author or coauthor of many journal articles. Dr. Little is the recipient of the Canadian Veterinary Medical Association Small Animal Practitioner Award (2010), the NAVC Small Animal Speaker of the Year Award (2013), and the International Society of Feline Medicine/Hill's Pet Nutrition Award for outstanding contributions to feline medicine (2013). She is the editor and co-author of *The Cat – Clinical Medicine and Management* (2nd edition 2024) and *August's Consultations in Feline Internal Medicine*, Volume 7.



Questionnaire

1. **Which class of oral diabetes mellitus medication does velagliflozin belong to?**
 - ☐ Glucagon-like peptide-1 receptor agonists
 - ☐ Alpha-glucosidase inhibitors
 - ☒ Sodium-glucose cotransporter 2 inhibitors
2. **What is the function of the sodium-glucose cotransporter 2 proteins in the kidney?**
 - ☒ Reabsorption of filtered glucose in urine
 - ☐ Excretion of glucose into urine
 - ☐ Blocking movement of glucose into urine
3. **Which of the following mechanisms does not apply to sodium-glucose cotransporter 2 inhibitors in the kidney?**
 - ☐ Reduction in reabsorption of filtered glucose
 - ☐ Promotion of urinary glucose excretion
 - ☒ Promotion of urinary glucose reabsorption
4. **Approximately what percentage of diabetic cats are successfully treated with sodium-glucose cotransporter 2 inhibitors?**
 - ☐ Less than 33%
 - ☐ About 50%
 - ☒ At least 80%
5. **Which of the following is the most important adverse event associated with sodium-glucose cotransporter 2 inhibitors?**
 - ☐ Urinary tract infection
 - ☒ Diabetic ketoacidosis
 - ☐ Hypoglycemia
6. **Which of the following is true about risk of clinical hypoglycemia in cats treated with sodium-glucose cotransporter 2 inhibitors?**
 - ☐ It is a common adverse event
 - ☒ It is a rare adverse event
 - ☐ It occurs as often as in cats treated with insulin
7. **Which of the following is the most important ketone body in cats?**
 - ☒ Beta-hydroxybutyrate
 - ☐ Acetoacetate
 - ☐ Acetone



8. Which of the following is most important to monitor in the first 14 days after treatment with a sodium-glucose cotransporter 2 inhibitor is started?
 - ☐ Blood glucose
 - ☐ Serum fructosamine
 - ☒ Ketones

9. Which of the following clinical signs may not completely resolve in diabetic cats receiving a sodium-glucose cotransporter 2 inhibitor?
 - ☐ Polyuria
 - ☒ Polyphagia
 - ☐ Polydipsia

10. Which of the following conditions is a contraindication for treatment of diabetic cats with a sodium-glucose cotransporter 2 inhibitor?
 - ☒ Pancreatitis
 - ☐ Food-responsive enteropathy
 - ☐ Feline idiopathic cystitis



COMMUNIVET™

PERSONAL INFORMATION:

First name:

Last name:

Type:

(Veterinarian, Technician)

Licence number:

Province where you practise:

Email:



COMMUNIVET™

CERTIFICATE OF COMPLETION

Educational webcast

It's been a year! What have we learned about velagliflozin?

Presented by

Susan Little, DVM, Dipl. ABVP (Feline Practice)

This document confirms that

Dr. Lorem Ipsum

has viewed the above-mentioned webcast and has answered and submitted the questionnaire meant to evaluate the understanding of the content.

Date:

Province of licensure:

Licence number:

CE credit (s) earned: 1